Definitive Contract 75N93026C00013
Award Date 8/3/26
Potential Completion Date 7/31/28
Potential Value $9.3M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Memphis, TN 38103, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
20
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Food and Drug Administration (FDA) awarded a $503,739 definitive cost-no-fee contract to the University of Tennessee to conduct research on the evaluation of small animal models for COVID-19 and their application in nonclinical safety and efficacy studies of investigational therapeutics. This contract is not associated with a set-aside program. As a major public research institution and land-grant university, the University of Tennessee has extensive expertise in medical research,...
- The University of Tennessee, doing business as Finance and Operation, was awarded a $623,991 Cost No Fee contract from the Food and Drug Administration (FDA) to conduct a longitudinal quantitative evaluation of the clinical, immunological, and virological characteristics of COVID-19 in mucosal, blood, and fecal specimens from adults, children, and exposed household members. This contract is not set aside. The University of Tennessee is a major public research institution and land-grant...
- The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Vanderbilt University Medical Center for B-cell epitope discovery and mechanisms of antibody protection on September 16, 2019, with a ceiling value of $10.244 million and no set-aside. The contract carries cost-plus-no-fee pricing. Place of performance is Nashville, Tennessee. The award addresses de-obligation of unexpiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) prior to...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Vanderbilt University Medical Center on July 17, 2017, with a ceiling value of $3,506,544.04 under the Vaccine and Treatment Evaluation Units (VTEU) parent IDIQ. The delivery order funds Task C Option 1 supporting VTEU operations at Nashville, TN. The order re-obligates FY16 funds in the amount of $785,402.77 and carries an ultimate completion date of January 31, 2021. Pricing is structured as cost no fee with...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded a $26,339,000.67 definitive cost-no-fee contract to Vanderbilt University in Nashville, Tennessee, for the "Evaluation of Control Measures Against Diseases Other Than AIDS." This contract, which does not have a set-aside designation, was awarded on June 15, 2002, with a performance period through March 8, 2008. Vanderbilt University is a leading private...
- This is a $24,919 firm-fixed price purchase order contract awarded by the U.S. Food and Drug Administration (FDA) to the University of Tennessee to develop standard operating procedures (SOPs) to ensure viral inactivation in various maternal and fetal tissue samples and blood prior to shipment to the FDA's National Center for Toxicological Research (NCTR). The contract has no set-aside designation and was awarded on July 8, 2021, with a completion date of July 7, 2022. The University of...
- This is a non-severable definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to the University of Montana for a base period of three years from September 30, 2018, to September 29, 2021, with a total potential value of $18,280,011.02 and an ultimate completion date of July 14, 2025. The contract is a cost-no-fee arrangement and does not have a set-aside designation. The...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $371,424 firm fixed price delivery order to Southern Research Institute under the In Vitro Assessments of Antimicrobial Activity indefinite-delivery/indefinite-quantity master contract vehicle. The delivery order is to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in Groups 8 and 9, as...
- The National Institute of Allergy and Infectious Diseases awarded a $6.78 million definitive contract to Translational Genomics Research Institute on September 30, 2024, for mycobacterium tuberculosis proteome-wide epitope discovery and host transcriptome-wide T cell phenotyping in high-disease-burden populations. The contract carries a cost-no-fee pricing structure. Performance occurs in Phoenix, Arizona, with an ultimate completion date of September 29, 2027. The originating...